Ferrol Hospital Complex (CHUF)

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Head of the Endocrinology and Nutrition Department at the Ferrol Hospital Complex (CHUF) and President of the Spanish Society for Obesity (SEEDO)

Contents related to this centre
obesity

Body mass index (BMI), commonly used to diagnose obesity, does not take into account differences in body composition or the distribution of body fat, which can affect health risks. A study published in Nature, using data from more than 844,000 adults in China, the United Kingdom, the United States and Spain, finds that incorporating other measures such as waist circumference and the waist-to-height ratio allows for the identification of between 3.3 per cent and 7.4 per cent more cases of obesity. The research also assesses the distinction proposed in 2025 between clinical obesity – when it is already affecting the body’s functioning – and preclinical obesity – when it is not yet doing so – as the former is associated with a higher risk of death.

Grasa

A person’s waist circumference is a better indicator of the risk of cardiovascular disease than body mass index (BMI) alone, according to a study published in the Journal of the American College of Cardiology. BMI has been used to determine overweight or obesity, common risk factors for heart disease, but this research — which analysed data from nearly 260,000 people with an average follow-up of 20 years — shows that failing to take waist circumference (WC) or the waist-to-hip ratio (WHR) into account can lead to an incorrect assessment of the risk of cardiovascular disease.

 

Semaglutida

Oral semaglutide is not effective in slowing the progression of the disease in patients with mild Alzheimer’s disease, according to the findings of the first large-scale, randomised phase 3 clinical trials published in The Lancet. In these trials, around 3,800 patients aged between 55 and 85 with a confirmed diagnosis and mild symptoms received up to 14 mg daily of oral semaglutide or a placebo. After two years, no significant difference in disease progression was observed.